PharmaDrug

Toronto-based PharmaDrug is a specialty pharmaceutical company that focuses on developing treatments based on controlled substances and natural medicines such as psychedelics and cannabis. The company operates three subsidiaries: PharmaDrug GmbH, a legal medical cannabis distributor in Germany and the EU; Super Smart, an adult-use psychedelic retail business; and Sairiyo Therapeutics, a biotech company focusing on natural therapeutics.

Founded in 2011, PharmaDrug claims to be the first company in the world to receive Orphan Drug Designation (ODD), a special status given to rare disease treatments, from the US Food and Drug Administration (FDA) to the psychedelic substance, dimethyltryptamine (DMT) for the prevention of ischemia-reperfusion injury (IRI) from organ transplant surgery. The company acquired Sairiyo Therapeutics in January 2021 and has been listed on the Canadian Securities Exchange since August 2018 under the ticker symbol “PHRX” (previously “BUZZ”).

Key Customers and Partnerships

In February 2023 , PharmaDrug entered into a partnership with PharmaTher, a psychedelic-focused drug developer, to study the delivery of N,N-dimethyltryptamine (DMT) using PharmaTher’s novel microneedle patch (MN- patch) delivery technology. Going forward, both companies will continue to work on product and clinical development, leading to initiating regulatory discussions for the use of the DMT MN-patch for various mental health conditions such as major depressive disorder.